Bcl-2 Binds Multiple Bax, Blocking Cancer Cell Death
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Bcl-2 was shown by advanced neutron scattering experiments to capture and bind several Bax proteins simultaneously on the mitochondrial outer membrane, enhancing inhibition of apoptosis.
- Cancer cells need only a moderate increase in Bcl-2 levels to evade therapy‑induced apoptosis, contradicting the notion that massive overexpression is required.
- Cardiolipin in the mitochondrial membrane promotes Bax pore formation, yet high Bcl-2 levels can still block apoptosis even when cardiolipin is present.
- Umeå University led the study, collaborating with Lund University, the European Spallation Source, ISIS Neutron and Muon Source, Diamond Light Source, and the Institut Laue‑Langevin.
- Gerhard Gröbner said the mechanistic insight could enable new cancer therapies that target Bcl‑2’s protective function.
- ACS Chemical Biology published the findings (Sophie E. Ayscough et al., 2026) describing Bcl‑2‑driven Bax oligomerization on membrane surfaces.
Why it matters: Oncologists gain a clearer target for drug development, as the research shows that inhibiting Bcl‑2 could restore apoptosis in tumors that rely on modest Bcl‑2 elevations, while cancer cells lose a key survival mechanism and may become more vulnerable to chemotherapy and radiotherapy.
Ask SkimNews
